⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
APVO News
Aptevo Therapeutics Inc
Form 8-K
sec.gov
APVO
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
accessnewswire.com
APVO
Ixinity (Medexus Pharma) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
XOMA
APVO
Ixinity (Medexus Pharma) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
XOMA
APVO
Form 8-K
sec.gov
APVO
eVTOL Aircraft Market worth $5.08 billion by 2035 - Exclusive Report by MarketsandMarkets™
prnewswire.com
JOBY
EH
EVEX
APVO
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
accessnewswire.com
APVO
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
accessnewswire.com
APVO
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
accessnewswire.com
APVO
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
accessnewswire.com
APVO